Skip to Content

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma.

The combination of daratumumab (Darzalex), ixazomib (Ninlaro), and dexamethasone showed promising results when administered to patients with relapsed/refractory multiple myeloma who had previously received lenalidomide (Revlimid) treatment. These phase 2 DARIA trial results were presented at EHA23 and again in this MEDtalk by Professor Evangelos Terpos from the National and Kapodistrian University of Athens in Greece.

Evangelos Terpos

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top